Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells

PARP inhibitors (PARPis) have been used to induce synthetic lethality in BRCA-deficient tumors in clinical trials with limited success. We hypothesized that RAD52-mediated DNA repair remains active in PARPi-treated BRCA-deficient tumor cells and that targeting RAD52 should enhance the synthetic leth...

Descripción completa

Detalles Bibliográficos
Autores principales: Sullivan-Reed, Katherine, Bolton-Gillespie, Elisabeth, Dasgupta, Yashodhara, Langer, Samantha, Siciliano, Micheal, Nieborowska-Skorska, Margaret, Hanamshet, Kritika, Belyaeva, Elizaveta A., Bernhardy, Andrea J., Lee, Jaewong, Moore, Morgan, Zhao, Huaqing, Valent, Peter, Matlawska-Wasowska, Ksenia, Müschen, Markus, Bhatia, Smita, Bhatia, Ravi, Johnson, Neil, Wasik, Mariusz A., Mazin, Alexander V., Skorski, Tomasz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6082171/
https://www.ncbi.nlm.nih.gov/pubmed/29898385
http://dx.doi.org/10.1016/j.celrep.2018.05.034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6082171/
https://www.ncbi.nlm.nih.gov/pubmed/29898385
http://dx.doi.org/10.1016/j.celrep.2018.05.034

Ejemplares similares